U.S. patent number RE38,008 [Application Number 09/995,870] was granted by the patent office on 2003-02-25 for methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof.
This patent grant is currently assigned to NeoRx Corporation. Invention is credited to Paul G. Abrams, Alton C. Morgan, Jr., Robert W. Schroff.
United States Patent |
RE38,008 |
Abrams , et al. |
February 25, 2003 |
**Please see images for:
( Certificate of Correction ) ** |
Methods for improved targeting of antibody, antibody fragments,
hormones and other targeting agents, and conjugates thereof
Abstract
Methods for improved targeting of antibody, antibody fragments,
peptides hormones, steroid hormones and conjugates thereof are
disclosed. Enhanced delivery to target cells of antibodies or
fragments thereof or other receptor-mediated delivery system, such
as peptide, specific for a population of cells of a mammal
comprises steps of administering to said mammal an adequate dosage
of blocking antibodies or fragments thereof or other
receptor-mediated delivery system, such as peptide, and
administering to said mammal an effective dosage of said antibodies
or fragments thereof or other receptor-mediated delivery system,
such as peptide, specific for said population of cells. In the
preferred embodiment, the specific antibodies are monoclonal
antibodies directed toward tumor-associated antigen in man.
Inventors: |
Abrams; Paul G. (Seattle,
WA), Schroff; Robert W. (Edmonds, WA), Morgan, Jr.; Alton
C. (Edmonds, WA) |
Assignee: |
NeoRx Corporation (Seattle,
WA)
|
Family
ID: |
46280182 |
Appl.
No.: |
09/995,870 |
Filed: |
November 29, 2001 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
917176 |
Oct 9, 1986 |
|
|
|
Reissue of: |
107136 |
Oct 9, 1987 |
05034223 |
Jul 23, 1991 |
|
|
Current U.S.
Class: |
424/138.1;
424/1.11; 424/141.1; 424/178.1; 424/179.1; 424/180.1;
424/181.1 |
Current CPC
Class: |
A61K
47/6865 (20170801); C07K 16/3053 (20130101); A61K
38/00 (20130101) |
Current International
Class: |
A61K
47/48 (20060101); C07K 16/18 (20060101); C07K
16/30 (20060101); A61K 38/00 (20060101); A61K
039/395 (); A61K 039/44 () |
Field of
Search: |
;424/130.1,138.1,178.1,179.1,180.1,181.1,141.1,1.11 ;514/885 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
0 063 988 |
|
Nov 1982 |
|
EP |
|
0 222 617 |
|
May 1987 |
|
EP |
|
85/00522 |
|
Feb 1985 |
|
WO |
|
Other References
Abrams et al., "Localization and Biodistribution Studies of a
Monoclonal Antibody in Patients with Melanoma", Monoclonal
Antibodies and Cancer Therapy, 233-236 (1985). .
Badger et al., "Experimental Radioimmunotherapy with I-131-Antibody
Against a Differentiation Antigen", J Nucl Med, 26, Abstract 279,
p. 67 (1985). .
Badger et al., "Experimental Radioimmunotherapy of Murine Lymphoma
with .sup.131 I-labeled Anti-T-Cell Antibodies", Cancer Research,
46, 6223-6228 (1986). .
Bancroft et al., "Manual of Histological Techniques", Publisher is
Churchill Livingstone, NY, p. 200 (1984). .
Carrasquillo et al., "Radioimmunodetection of Cutaneous T-Cell
Lymphoma with .sup.111 In-Labeled T101 Monoclonal Antibody", The
New England Journal of Medicine, 315, 673-680 (1986). .
Casellas et al., "Human Melanoma Cells can be Killed in Vitro by an
Immunotoxin Specific for Melanoma-Associated Antigen p. 97", Int J
Cancer, 30, 437-443 (1982). .
DeNardo et al., "Evidence of a Saturable Hepatic Receptor for Mouse
Monoclonal Antibodies", J Nucl Med, 26, Abstract 277, p. 67 (1985).
.
Epenetos et al., "Targeting of Iodine-123-Labeled Tumour-Associated
Monoclonal Antibodies to Ovarian, Breast, and Gastrointestinal
Tumours", The Lancet, 999-1004 (Nov. 6, 1982). .
Ettinger et al., "Phase I-II Study of Isotopic Immunoglobulin
Therapy for Primary Liver Cancer", Cancer Treatment Reports, 66,
289-297 (1982). .
Foon et al., "Effects of Monoclonal Antibody Therapy in Patients
with Chronic Lymphocytic Leukemia", Blood, 64, 1085-1093 (1984).
.
Gilliland et al., "Antibody Directed Cytotoxic Agents: Use of
Monoclonal Antibody to Direct the Action of Toxin A Chains to
Colorectal Carcinoma Cells", PNAS USA, 77, 4539-4543 (1980). .
Halpern et al., "Radioimmunodetection of Melanoma Utilizing In-111
96.5 Monoclonal Antibody: A Preliminary Report", Radiology, 155,
493-499 (1985). .
Hetzelberger et al., "Idiotypic Suppression: III. Induction of
Unresponsiveness to Sensitization with Anti-Idiotypic Antibody:
Identification of the Cell Types Tolerized in High Zone and in Low
Zone, Suppressor Cell-Mediated, Idiotype Suppression", Eur J
Immunol, 8, 839-846 (1978). .
Hwang et al., "Dynamic Interaction of .sup.111 Indium-Labeled
Monoclonal Antibodies with Surface Antigens of Solid Tumors
Visualized in Vivo by External Scintigraphy", JNCI, 76, 849-855
(1986). .
Kanellos et al., "Studies of Methotrexate-Monoclonal Antibody
Conjugates for Immunotherapy", JNCI, 75, 319-329 (1985). .
Koizumi et al., "Multicompartmental Analysis of the Kinetics of
Radioiodated Monoclonal Antibody in Patients with Cancer", J Nucl
Med, 27, 1243-1254 (1986). .
Koopman et al., "Suppression of in Vitro Monoclonal Human
Rheumatoid Factor Synthesis by Antiidiotypic Antibody", J Clin
Invest, 72, 1410-1419 (1983). .
Larson et al., "Localization of .sup.131 I-Labeled p 97-Specific
Fab Fragments in Human Melanoma as a Basis for Radiotherapy", J
Clin Invest, 72, 2101-2114 (1983). .
Larson et al., "Use of I-131 Labeled, Murine Fab against a High
Molecular Weight Antigen of Human Melanoma: Preliminary
Experience", Radiology, 155, 487-492 (1985). .
Letvin et al., "Use of Radiolabeled Monoclonal Anti-B1 Antibody for
B Lymphocyte Imaging in Rhesus Monkeys", Nucl. Med. Biol., 14,
99-105 (1987). .
Meeker et al., "A Clinical Trial of Anti-Idiotype Therapy for B
Cell Malignancy", Blood, 65, 1349-1363 (1985). .
Miller et al., "Treatment of B-Cell Lymphoma with Monoclonal
Anti-Idiotype Antibody", The New England Journal of Medicine, 306,
517-522 (1982). .
Murray et al., "Radioimmunoimaging in Malignant Melanoma with
.sup.111 In Labeled Monoclonal Antibody 96.5"Cancer Res, 45,
2376-2381 (1985). .
Ohkawa et al., "Selective in Vitro and in Vivo Growth Inhibition
Against Human Yolk Sac Tumor Cell Lines by Purified Antibody
Against Human .alpha.-Fetoprotein Conjugated with Mitomycin C via
Human Serum Albumin", Cancer Immunol Immunother, 23, 81-86 (1986).
.
Oldhan et al., "Monoclonal Antibody Therapy of Malignant Melanoma:
In Vivo Localization in Cutaneous Metastasis After Intravenous
Administration", J Clin Oncology, 2, 1235-1244 (1984). .
Order, "Monoclonal Antibodies: Potential Rule in Radiation Therapy
and Oncology", Int. J. Radiation Oncology Biol. Phys., 8, 1193-1201
(1982). .
Order et al., "Phase I-II Study of Radiolabeled Antibody Integrated
in the Treatment of Primary Hepatic Malignancies", Int. J.
Radioation Oncology Biol. Phys., 6, 703-710 (1980). .
Press et al., "Monoclonal Antibody 1F5 (Anti-CD20) Serotherapy of
Human B Cell Lymphomas", Blood, 69, 584-591 (1987). .
Ramakrishnan et al., "Immunological and Biological Stability of
Immunotoxins in Vivo as Studied by the Clearance of
Disulfide-Linked Pokeweed Antiviral Protein-Antibody Conjugates
from Blood", Cancer Research, 45, 2031-3036 (1985). .
Rosen et al., "Radioimmunodetection and Radioimmunotherapy of
Cutaneous T Cell Lymphomas Using an .sup.131 I-Labeled Monoclonal
Antibody: An Illinois Cancer Council Study", Journal of Clinical
Oncology, 5, 562-573 (1987). .
Rowland et al., "Antitumor Properties of Vindesine-Monoclonal
Antibody Conjugates", Cancer Immunol Immunother, 19, 1-7 (1985).
.
Stashenko et al., "Characterization of a Human B
Lymphocyte-Specific Antigen", The Journal of Immunology, 125,
1678-1685 (1980). .
Tagliabue et al., "Improvement of Tumor Cell Detection Using a Pool
of Monoclonal Antibodies", Hybridoma, 5, 107-115 (1986). .
Thielemans et al., "Strategies for Production of Monoclonal
Anti-Idiotype Antibodies Against Human B Cell Lymphomas", J
Immunology, 133, 495-501 (1984). .
Weinstein et al., "Monoclonal Antibodies in the Lymphatics: Toward
the Diagnosis and Therapy of Tumor Metastases", Science, 218
1334-1337 (1982). .
Pastan, I., et al., "Recombinant Toxins for Cancer Treatment",
Science, 254, (1991), 1173-1177..
|
Primary Examiner: Mertz; Prema
Attorney, Agent or Firm: Schwegman, Lundberg, Woessner &
Kluth, P.A.
Parent Case Text
CROSS-REFERENCE TO RELATED APPLICATION
This application is a continuation-in-part of co-pending
application Ser. No. 917,176, filed Oct. 9, 1986 now abandoned.
Claims
We claim:
1. A method of enhancing delivery to solid tumor target cells
within a mammal of conjugated specific antibodies or fragments
thereof pharmaceutically active and specific for said target cells,
comprising the steps of: administering to said mammal an adequate
dosage of blocking antibodies or fragments thereof, said blocking
antibodies being capable of blocking the binding of the conjugated
specific antibodies or fragments thereof to non-target tissue(s)
through antigen recognition; and then administering to said mammal
a .[.diagnostically or.]. therapeutically effective dosage of said
conjugated specific antibodies or fragments thereof, said
conjugated specific antibodies being specific for said solid tumor
target cells.
2. The method of claim 1 wherein said blocking antibodies or
fragments thereof are capable of cross-reactive, epitope-specific
binding to non-target cells.
3. The method of claim 1 wherein said antibody fragments are
selected from the group consisting of F(ab)', F(ab)'.sub.2, Fab,
Fv, and mixtures thereof.
4. The method of claim 1 wherein said solid tumor target cells are
characterized by having tumor-associated antigen.
5. The method of claim 1 wherein any of the antibodies are
monoclonal antibodies.
6. The method of claim 1 wherein any of the antibodies are
polyclonal antibodies.
7. The method of claim 1 wherein the conjugated specific antibodies
comprise antibodies or fragments thereof specific for said target
cells conjugated to a cytotoxin.
8. The method of claim 1 wherein the conjugated specific antibodies
comprise antibodies or fragments thereof specific for said target
cells conjugated to a radionuclide..[.
9. The method of claim 1 wherein the effective dosage of conjugated
specific antibodies or fragments thereof is diagnostically
effective..]..[.
10. The method of claim 1 wherein the effective dosage of
conjugated specific antibodies or fragments thereof is
therapeutically effective..].
11. The method of claim 1 wherein the mammal is a human.
12. The method of enhancing the localization at a solid tumor
target site of conjugated specific antibodies or fragments thereof
specific for an antigen contained on the target site and also on a
non-target tissue or organ within a mammal, comprising the steps
of: perfusing said non-target tissue or organ with an adequate
dosage of blocking antibodies or fragments thereof, said blocking
antibodies being capable of blocking the binding of the conjugated
specific antibodies or fragments thereof to non-target tissue(s) or
organ through antigen recognition; and administering to the mammal
a diagnostically or therapeutically effective dosage of said
conjugated specific antibodies or fragments thereof specific for
said antigen.
13. The method of claim 12 wherein said blocking antibodies or
fragments thereof are capable of cross-reactive, epitope-specific
binding to the non-target tissue or organ.
14. The method of claim 12 wherein said antibody fragments are
selected from the group consisting of F(ab)', F(ab)'.sub.2, Fab,
Fv, and mixtures thereof.
15. The method of claim 12 wherein said tissue or organ is
characterized by having tumor-associated antigen.
16. The method of claim 12 wherein the antibodies are monoclonal
antibodies.
17. The method of claim 12 wherein the antibodies are polyclonal
antibodies.
18. The method of claim 12 wherein the conjugated specific
antibodies comprise antibodies or fragments thereof conjugated to a
cytotoxin .[.or drug.]. .
19. The method of claim 12 wherein the conjugated specific
antibodies comprise antibodies or fragments thereof conjugated to a
radionuclide.
20. The method of claim 12 wherein the blocking antibodies or
fragments thereof and the conjugated specific antibodies or
fragments thereof are administered simultaneously.
21. The method of claim 12 wherein the blocking antibodies or
fragments thereof are administered prior to the conjugated specific
antibodies or fragments thereof.
22. The method of claim 12 wherein the effective dosage of said
conjugated specific antibodies or fragments thereof is
diagnostically effective.
23. The method of claim 12 wherein the effective dosage of said
conjugated specific antibodies or fragments thereof is
therapeutically effective.
24. The method of claim 12 wherein the mammal is a human.
25. The method of .[.targeting.]. .Iadd.treating .Iaddend.melanoma
in humans, comprising the steps of: administering to said human an
adequate dosage of unlabeled specific antibody or fragment thereof
that binds to a melanoma-associated antigen; and then administering
to said human a .[.diagnostically.]. or therapeutically effective
dose of labeled specific antibody or fragment thereof that binds to
the same epitope of the melanoma-associated antigen as the
unlabeled specific antibody.
26. The method of claim 25 wherein the antibody or fragment thereof
that binds to a melanoma-associated antigen recognized the 250 Kd.
blycoprotein/proteoglycan.
27. The method of claim 25 wherein the antigen-binding region of
the antibody or fragment thereof is selected from the group
consisting of antigen-binding regions of antibodies 9.2.27 and
NR-ML-05, and their clones, chimaeras and derivatives.
28. The method of claim 25 wherein the antigen-binding region of
the antibody or fragment thereof recognizes the G.sub.D3 glycolipid
melanoma-associated antigen.
29. The method of claim 25 wherein the antigen-binding region of
antibody or fragment thereof recognizes the P97 melamona-associated
antigen.
30. A method of enhancing delivery to solid tumor target cells
within a mammal of conjugated specific antibodies or fragments
thereof pharmaceutically active and specific for said target cells,
comprising the steps of: administering to said mammal an adequate
dosage of blocking antibodies or fragments thereof; wherein said
blocking antibodies are the unconjugated form of the conjugated
specific antibodies or fragments thereof; and then administering to
said mammal a .[.diagnostically or.]. therapeutically effective
dosage of said conjugated specific antibodies or fragments thereof,
and conjugated specific antibodies being specific for said solid
tumor target cells.
31. The method of claim 30 wherein the conjugated specific
antibodies comprise antibodies or fragments thereof specific for
said target cells conjugated to a radionuclide..Iadd.
32. A method of enhancing delivery to tumor target cells within a
mammal of conjugated specific antibodies or fragments thereof
pharmaceutically active and specific for said target cells,
comprising the steps of: administering to said mammal an adequate
dosage of antibodies or fragments thereof, wherein said antibodies
bind to melanoma, colon cancer or lymphoma target cells, and
wherein said antibodies are the unconjugated form of the conjugated
specific antibodies or fragments thereof; and then administering to
said mammal a therapeutically effective dosage of said conjugated
specific antibodies or fragments thereof, said conjugated specific
antibodies being specific for said tumor target
cells..Iaddend..Iadd.
33. The method of claim 1 or 32 wherein the conjugated specific
antibodies are conjugated to a radioisotope..Iaddend..Iadd.
34. The method claim 33 wherein the radioisotope is .sup.131
I..Iaddend..Iadd.
35. The method of claim 1 or 30, wherein the target cells are
melanoma cells, colon carcinoma cells, or lymphoma cells..Iaddend.
Description
1. Technical Field
The present invention generally relates to methods for enhancing
targeting of antibodies, antibody fragments, peptide hormones and
steroid hormones, and conjugates thereof. More specifically,
methods are disclosed employing blocking antibodies, fragments,
hormones and other targeting agents, and conjugates thereof to
reduce cross-reactive and nonspecific binding of specific
antibodies, hormones and other targeting agents to non-target
cells.
2. Background Art
Antibodies are proteins that have a binding site that is specific
for a particular determinant, e.g., antigen or epitope, and other
portions that bind to normal tissues in a nonspecific fashion.
There are several immunological concepts, all related to antibody
binding, that require definition.
Target-specific binding: Binding of the antibody, whole or
fragment, hormones, other targeting agents or conjugate thereof,
through the antibody's binding site, to the epitope recognized by
said antibody on cells expressing said epitope's or hormone's
receptor, where said cells are the desired target of the antibody,
whole or fragment, or hormone, other targeting agent, or conjugates
thereof.
An example of target-specific binding is binding of the antibody,
whole or fragment, or conjugate thereof, to tumor cells where the
antibody in question can also bind specifically to normal cells.
The component of binding to the tumor cells is target-specific.
Another example is binding of bombesin, or gastrin-releasing
peptide, to small cell lung carcinoma.
Cross-reactive binding: Binding of the antibody, whole or fragment
or hormone, other targeting agent or conjugate thereof, through the
antibody's binding site, to the epitope recognized by said antibody
on cells expressing said epitope or hormone receptor, where said
cells are not the desired target of the antibody, whole or
fragment, or hormone or conjugate thereof.
An example of cross-specific binding is binding of the antibody,
whole or fragment, or conjugate thereof, to normal lung by antibody
binding site to the same or structurally homologous epitope as is
present on a tumor cell. The component of binding to the normal
lung cells by the antigen-binding site of the antibody is
cross-reactive. Another example is the binding of bombesin, or
gastrin-releasing peptide, to normal cells in the stomach or
pancreas.
Nonspecific binding: Binding of an antibody, whole or fragment, or
hormone or conjugate thereof, through some mechanism other than the
antigen-recognition binding site of the antibody or hormone, to
cells other than the target cells.
An example of nonspecific binding is the uptake of antibody into
the liver and spleen due to binding of the antibody by its Fc
receptors onto cells in these organs.
A second example would be binding of mannose present in the ricin
of antibody-ricin conjugate to mannose receptors on liver
cells.
Specific antibody: Antibody that binds to epitope on desired target
cells through its antigen-recognition sites. Specific antibodies
may also bind to epitope or structural homolog present on
non-target cells.
Irrelevant antibody: Antibody that does not bind to target cells by
means of its antigen-recognition sites, but may bind to non-target
and target cells through non-specific mechanisms, e.g., Fc portion
of antibody binding to Fc receptors on cells in reticuloendothelial
system (RES).
Blocking antibody: Antibody that inhibits the non-specific binding
of pharmaceutically active specific antibody. Blocking antibodies
may include irrelevant antibody or pharmaceutically inactive
specific antibody or fragments or combinations thereof. The latter
may also be called "cold-specific" antibody.
Pharmaceutically active antibody: Antibody that is diagnostically
or therapeutically effective.
The use of antibodies are carriers for radionuclides and cytotoxins
has been a goal of cancer of diagnosis and treatment since Pressman
et al. showed that 131.sub.I labeled rabbit anti-rat kidney
antibodies localized in the kidney after intravenous injection
(Pressman, D., Keighly, G. (1948) J. Immunol. 59:141-46). Just a
few years later, Vial and Callahan reported a dramatic, complete
response in a patient with widely metastatic malignant melamoma
treated with .sup.131 I-antibodies raised against his own tumor
(Vial, A. B. and Callahan, W. (1956), Univ. Mich. Med. Bull. 20:
284-86). In the 1960s, Bale and co-workers demonstrated that
labeled antibodies to fibrin, which is often deposited in rapidly
growing tumors, could localize in rat, dog and human tumors (65% of
141 patients) (Bale, W. F., et al. (1960) Cancer Res. 20:1501-1504
(1960); McCradle, R. J., Harper, P. V., Spar, I. L., et al., (1966)
J. Nucl. Med. 7:837-44; Spar, I. L., Bale, W. F., Manack, D., et
al. (1969) Cancer 78:731-59; Bale, W. F., Centreras, M. A., Goody,
E. D. (1980) Cancer Res. 40:3965-2972). Several years later, Chao
et al. demonstrated selective uptake of antibody fragments in
tumors (Chao, H. F., Peiper, S. C., Philpott, G. W., et al. (1974)
Res. Comm. in Chem. Path. & Pharm. 9:749-61).
Monoclonal antibodies (Kohler, G. and Milstein, C. (1975) Nature
256:495-97) offer advantages over the polyclonals used in these
studies because of their improved specificity, purity and
consistency among lots. These factors, plus their wide
availability, have let to improved clinical applications of
antibodies and their conjugates.
Even with monoclonals, however, most antibodies to human tumors
have some normal tissue cross-reactivity. Compared to tumors, these
cross-reactive sites may equally or preferentially bind injected
antibody or conjugate and thus adsorb a substantial portion of the
administered dose, especially if these sites are concentrated in
well-perfused organs. If the antibody is conjugated to a toxin
agent, there may be toxicity to the normal tissues that could be
dose-limiting. Therefore, reducing normal tissue binding of the
antibody or conjugates without adversely affecting their tumor
localization would be advantageous.
Also needed in the art are methods to improve the targeting of
immunoconjugates to tumor cells. Most immunoconjugates are produced
by chemically linking an antibody to another agent. Another
possibility is creating a fusion protein. The antibody itself, the
process of linking, or the conjugated agent itself may cause
decreased localization of the tumor due to nonspecific or
cross-reactive binding.
Also needed in the art is a method to improve delivery of
cytotoxins or biologic response modifiers (BRMs) to tumors using
antibodies as carriers, while minimizing toxicity.
Also needed in the art are similar methods to improve delivery of
cytotoxins or biologic response modifiers (BRMs) to tumors using
hormones or other targeting agents as carriers, while minimizing
toxicity.
Also needed in the art is a method to decrease formation of
antiglobulins to injected antibody or immunoconjugates as there may
be inhibition of binding or even toxicity when the same antibody is
injected at a later time.
All of these issues can be addressed by the described methods that
reduce cross-reactive and nonspecific binding of antibody and
antibody conjugates, and are equally applicable to any substance
that has a nonspecific uptake site or whose receptors are shared by
non-target cells.
The methods of the present invention reduce cross-reaction and/or
nonspecific binding of specific antibodies and hormones when
administered to diagnose, stage, evaluate or treat diseases such as
cancer in humans. The characteristic or specificity makes
antibodies potentially useful agents for targeting defined
populations of cells such as tumor cells that express
tumor-specific (expressed uniquely by tumor cells) or
tumor-associated (expressed by tumor cells and by a subpopulation
of normal cells) antigens. The clinical utility of these specific
antibodies, however, is compromised by the phenomenon of
cross-reactive and nonspecific binding.
One method of markedly diminishing nonspecific uptake is to remove
a nonspecific binding portion of the antibody, leaving the antigen
binding portion [e.g., F(ab)'.sub.2', Fab or Fv]. Fragments may
accumulate more rapidly onto the tumor cell than whole antibody due
to their smaller size, which facilitates egress from the
circulation across blood vessel and capillary walls into the tumor
bed. This does not usually compensate for the decreased serum
half-life of the fragments resulting in decreased tumor
accumulation compared to whole antibody. Thus there exists a need
to prolong serum half-life of fragments in order to take advantage
of their more rapid accumulation in target cells and, therefore, to
improve localization into a tumor. Additionally, nonspecific
binding of specific antibodies into normal organs needs to be
decreased.
Generally, a major obstacle to the successful clinical use of
antibodies and conjugates thereof has been inadequate delivery to
target cells. This has been assessed both by immunohistochemistry
on frozen sections of tumors removed after antibody administration
(Oldham, R. K., Foon, K. A., Morgan, A. C., et al. (1984) J. of
Chem. Oncol. 2(11):1234-44; Abrams, P. G., Morgan, A. C., Schroff,
C. S. (1985) In: Monoclonal Antibodies and Cancer Therapy (Deisfeld
and Sell, Eds.), Alan R. Liss Inc., pp. 233-36) or by calculating
the percent of the radiolabeled antibody dose per gram in the tumor
(Murray, J. L., Rosenblum, M. G., Sobol, R. E., et al. (1985)
Cancer Res. 45: 2376-81; Carrasquillo, J. A., Abrams, P. G.,
Schroff, R. W. et al. (submitted); Epenetos, A. A., Mather, S.,
Gwanowska, M., et al. (1982) Lancett II:999-1004; Larson, S. M.,
Carrasquillo, J. A., Krohn, K. A., et al. (1983) J. Clin.
Investigation 72:2101-2114 (1983). There was clear evidence in the
former studies of increased antibody localization in tumor with
higher doses of specific antibody. The quantitative studies with
radiolabeled antibody have shown 0.0001%-0.0004% of the injected
dose/gram localizing to tumor (Carrasquillo, ibid.).
Radiolabeling of antibodies permits the quantitative assessment of
percent accretion into tumors and normal organs and disappearance
from the blood and the whole body. This serves as a paradigm for
the biodistribution and kinetrics of antibodies and
immunoconjugates. Conjugated or labeled peptides or steroid
hormones provide an analogous strategy.
Studies with radiolabled antibodies have demonstrated that part of
the problem causing low tumor accumulation is the localization of
radiolabeled antibody in other organs, such as liver, spleen,
marrow, lung or kidney. The prior art is replete with examples of
increasing mass of specific antibody to improve tumor localization
(e.g., Abrams, ibid.; Murray, ibid.; Carrasquillo, ibid.; Epenetos,
ibid.; Larson, ibid.) The present invention uses irrelevant
antibody to adsorb to these nonspecific sites, thus obviating the
requirement for large doses of unconjugated specific antibody
required in the prior art. One advantage of this strategy is that
unconjugated irrelevant antibody does not compete for specific
sites on target cells with conjugated specific antibody. Another
advantage is that irrelevant antibody skews the immunological
response to the patient away from the specific antibody (vide
infra).
One measure of decreased adsorption of specific antibody onto
nonspecific sites is prolonged serum half-life of the antibody.
Another unexpected result of pre-administering isotype and subclass
matched whole irrelevant immunoglobulin is the prolonged serum
half-life, reduced nonspecific adsorption and improved tumor
detection with fragments of specific antibody.
The prior art recognizes the problem of localizing specific
antibody and fragments and conjugates thereof due to nonspecific
and cross-reactive binding to non-target epitopes, e.g., Murray,
ibid. Yet, the solution employed has been to lump together the
problems of nonspecific and cross-reactive uptake and to use a
single strategy--co-administration of large masses of specific
unconjugated antibody--to overcome the problems. The present
invention not only distinguishes these problems, but also offers
different solutions to each: (1) the use of irrelevant antibody
(immunoglobulin) to reduce nonspecific and cross-reactive binding
of specific antibody, and (2) the administration of unconjugated
specific antibody to bind to cross-reactive sites prior to the
administration of conjugated specific antibody. The latter solution
applies equally to steroid and peptide hormones.
Since antibodies are proteins, in most cases of non-human origin,
the spectre of human antiglobulin and anti-idotype has been raised
(Oldham, ibid.; Abrams, ibid.; Murray, ibid.; Carrasquillo, ibid.;
Epenetos, ibid.; Larson, ibid.). This invention demonstrates that
the co-administration of large masses of irrelevant antibody can
skew the antiglobulin response toward the irrelevant antibody and
not the specific antibody so that, along with either the same or a
second irrelevant antibody, the same target-specific antibody can
be injected again and localize in tumor sites without significant
formation of antiglobulins to the specific antibody.
Despite their increased specificity, monoclonal antibodies thus far
have not been entirely tumor-specific, but rather recognize
tumor-associated antigens. When their cross-reactivity is
predominantly to one organ that can be selectively perfused, the
present invention provides methods for targeting specific antibody
conjugates by selective direct infusion of unconjugated specific
antibody into a vessel feeding a normal organ known to concentrate
conjugated antibody by cross-reactive binding. For a therapeutic
conjugate, the reduction in toxicity is a substantial
advantage.
Conjugates of specific antibody may localize in non-specific sites
due to the molecule linked to the antibody rather than the antibody
itself. The protein toxins (e.g., ricin, abrin, diphtheria toxin,
pseudomonas toxin) can bind to mammalian cells through particular
portions of these molecules. This property has prompted a large
effort to eliminate their nonspecific binding capability while
preserving the potency of the toxin. According to the methods of
the present invention, detoxified protein toxins, when conjugated
to nonspecific antibody, can reduce binding of the specific
antibody-toxin conjugate to nonspecific sites. this methodology
reduces whole organism toxicity and permits the administration of
large doses of the specific toxin conjugate.
DISCLOSURE OF THE INVENTION
The method of the present invention is for enhancement of delivery
to target cells of antibodies or fragments thereof or other
receptor-mediated delivery systems, such as peptide, specific for a
population of cells of a mammal. The method comprises the steps of
administering to said mammal an adequate dosage of blocking
antibodies or fragments thereof or other receptor-mediated delivery
systems, such as peptide, and administering to said mammal an
effective dosage of said antibodies or fragments thereof or other
agents that target a defined population of cells via receptors,
such as hormones, specific for said population of cells, the
blocking antibodies or fragments thereof or other targeting agents
capable of nonspecific and/or cross-reactive binding to non-target
cells. The antibody fragments of either the blocking antibodies or
the specific antibodies are selected from the group consisting of
F(ab)', F(ab)'.sub.2, Fab, Fv and mixtures thereof.
In a preferred embodiment, the target cells are characterized by
having tumor-associated antigen. Both the blocking antibodies and
the specific antibodies may be either monoclonal or polyclonal
antibodies. Furthermore, the specific antibodies and fragments
thereof may be conjugated to cytotoxins, radionuclides or
biological response modifiers.
The administration of the blocking antibodies is preferably done
prior to the administration of the specific antibodies;
alternatively, such blocking antibodies may be administered
simultaneously with the specific antibody. The effective dosage of
the antibodies or fragments thereof specific for a said population
of cells is either diagnostically effective or therapeutically
effective. The preferred mammal of the methods disclosed herein is
man.
An additional preferred embodiment of the methods disclosed herein
is for enhancement of the localization of antibodies or fragments
thereof specific for a cross-reactive antigen contained within a
mammal's tissue or organ. This method comprises the steps of
directly perfusing said tissue or organ with an adequate dosage of
blocking antibodies or fragments thereof and then administering
systemically to the mammal an effective dosage of said antibodies
or fragments thereof specific for said antigen contained within
said tissue or organ that is also present or target cells.
A related aspect of the present invention discloses a method for
reducing within a mammal the production of anti-immunoglobulin
directed against antibodies or fragments thereof specific for a
population of target cells. This method comprises the steps of
administering to said mammal in adequate dosage of blocking
antibodies or fragments thereof capable of stimulating the
production of anti-immunoglobulin directed against said blocking
antibodies or fragments thereof and administering to said mammal a
therapeutically effective dosage of said antibodies or fragments
thereof specific for said target cells, wherein said
therapeutically effective dosage is smaller than said adequate
dosage of blocking antibodies or fragments thereof.
BEST MODE FOR CARRYING OUT THE INVENTION
1. Reducing Nonspecific Uptake
An irrelevant antibody may be matched with a specific antibody by
species, isotype and/or subclass and is administered, usually in
several-fold or greater quantities, to patients prior to the
injection of the specific antibody or specific antibody conjugates.
Alternatively, such matching may not be necessary. The prior art
has demonstrated improved tumor localization of whole antibody with
increasing doses of specific antibody. These results were assessed
with either trace-labeled specific antibody or by
immunohistochemistry following antibody administration (Oldham,
ibid.; Abrams, ibid.; Murray, ibid.; Carrasquillo, ibid.). In the
former, the unlabeled, specific antibody was usually given
simultaneously with the labeled preparation. The underlying concept
involved providing sufficient mass of antibody to attach to
nonspecific sites, leaving more specific antibody available to bind
to tumor. There was some reduction of labeled antibody in
nonspecific sites (e.g., liver), and a marked increase in serum
half-life of the radiolabeled whole immunoglobulin (Carrasquillo,
ibid.). There is, however, the potential for competition for
specific binding at the tumor size by the labeled and unlabeled
antibody. If the label is used symbolically to represent any agent
conjugated to antibody, competition of unlabeled antibody for the
tumor antigen at the most accessible (perivascular) sites will
compromise the delivery of that agent to the tumor. In addition, a
percentage of the labeled antibody, when injected simultaneously,
behaves as a true tracer and deposits in normal nonspecific and
cross-reactived sites.
The method described herein uses irrelevant antibody (blocking
antibody) to reduce the nonspecific uptake, without competing for
the tumor antigen, preferably administered prior to specific
antibody (see Example I). The positive results observed by
pre-administering irrelevant antibody were not expected since human
gammaglobulins, in large (>1 gm) quantities, failed to show any
decreased localization of radiolabeled antibody into nonspecific
sites (Carrasquillo, ibid.).
Further, the method described herein is applicable to fragments of
specific antibody as well as to whole specific antibody. The method
also has been shown to increase the serum half-life of
fragments.
Particularly unexpected was the prolonged serum half-life in the
initial phase of serum clearance achieved by using whole irrelevant
antibody prior to specific antibody fragments. This was surprising
since it was assumed that the nonspecific binding sites on antibody
would be eliminated by creating fragments devoid of the Fc portion
of the molecule. This method is useful for reducing non-specific
binding of specific antibody, whole for fragment, or conjugates of
such antibody, whole or fragment, with radionuclides, drugs,
toxins, biologic response modifiers or differentiating agents.
2. Reducing Cross-Reactivity with Normal Tissues
Normal tissues may contain an epitope, or structural homolog of an
epitope, expressed on the target cell. Several methods to reduce
localization to non-target tissues are presented herein. For normal
tissues equally or more accessible than tumors to specific
antibody, unconjugated specific antibody (blocking antibody) is
administered prior to conjugated specific antibody (see Example
II). The antigen sites on normal tissues, such as blood vessels or
liver, will first bind the previously injected, unconjugated whole
antibody. In one embodiment, the blocking antibody is bivalent
(whole or F(ab'.sub.2) and the conjugated antibody is monovalent
(Fab', Fab or Fv). This approach taken advantage of the higher
antigen affinity of the bivalent molecules and thus reduces the
competition of the subsequently administered, conjugated monovalent
species for the cross-reactive sites.
The precise doses of the cold-specific antibody and the timing of
administration will be dependent upon the size of the patient, the
quantitative normal tissue expression of the antigen or epitope,
the relative accessibility of tumor compared to normal tissue
sites, and the purpose for which the entire procedure is being
performed. For example, a modest degree of nontumor targeting may
be acceptable in a therapeutic study as long as toxicity is
tolerable, but less acceptable in an imaging mode where false
positives could be a problem.
The dose of the cold-specific antibody can be approximated by
administering increasing doses of the cold-specific antibody prior
to biodistribution studies with a labeled antibody or labeled
conjugate. When normal tissue sites that show evidence of uptake of
the radiolabeled antibody or conjugate with no cold-specific
antibody are no longer visualized, than an adequate dose of the
cold-specific antibody will have been reached. Alternatively, a
greater interval may be allowed between the given does of
cold-specific antibody and the subsequent administration of
conjugated specific antibody to permit greater permeation of the
cold-specific antibody into normal tissues.
Another approach is to determine the serum half-life of an
irrelevant antibody or fragment and preadminister sufficient
cold-specific antibody or fragment to raise the half-life of the
conjugated antibody to fragment close to the half-life of the
irrelevant antibody. This would be indirect evidence that a normal
tissue antigen "sink" was completely or largely saturated.
An additional method of determining the appropriate dose has been
described by Eger et al. Using data obtained from patients
receiving the 9.2.27 antibody, they constructed a mathematical
model that, by regression analysis, could predict a dose of
antibody that would saturate the "antigen sink" in normal
tissues.
Once determined for a particular antigen-antibody system, the does
and schedule can be calculated on a body surface area or weight
basis for the particular antibody.
Within a wide range, however, the administration of more than a
normal tissue dose will have little effect on the delivery of the
conjugated antibody to the tumor. The major considerations are
saturation of the more accessible tumor sites and affinity
differencies between unconjugated, "cold" antibody and the
conjugate. If the conjugate has substantially less affinity, too
large a dose of unconjugated antibody will compete off the
conjugate and thus efficacy--therapeutic or detection--will be
reduced.
A second method for reducing cross-reactivity with normal tissues
that contain the cross-reactive associated antigen involves
directed prior or co-administration of unconjugated antibody (see
Example III). Generally, venous or arterial access is achieved
through percutaneous catheterization. For example, the renal
articles or veins may be catheterized to perfuse the kidneys
selectively. Alternatively, a catheter may be placed into an
appropriate vessel (e.g., hepatic artery for liver) at he time of
surgery. The unconjugated antibody is injected by the catheter to
contact the antigen sites of the normal organ with the "first pass"
of antibody. The antibody may be whole or fragmented. Either
simultaneously or thereafter, the conjugated antibody is injected
into the mammal's general circulation. Binding of the specific
conjugated antibody to the previously perfused sites in the normal
organs is reduced, thus increasing the availability of the
conjugated specific antibody for the target cells. The also results
in reduced toxicity to the cross-reactive, non-target organ by the
specific conjugated antibody.
A third method involves either peripheral vein or directed infusion
as described above. Instead of using unconjugated antibody as the
blocking antibody, a conjugate of antibody and detoxified cytotoxin
or BRM is infused where the detoxification (i.e., reduced toxicity)
process preserves the sites of recognition and/or binding by normal
cells (see Example IV). In a preferred embodiment, the detoxified
agent is either free or bound to the nonspecific antibody, and the
detoxified conjugate is injected prior to the administration of
specific antibody conjugate and, if necessary, may be administered
as a constant infusion.
In another method, where the tumor to be treated is localized in an
organ or a limb, conjugated antibody is injected via directed
catheter into the organ or limb following peripheral blockage of
cross-reactive and nonspecific sites with unconjugated specific
and/or deeoxified, conjugated irrelevant and/or unconjugated
irrelevant antibody.
An additional method provides for injection of unconjugated
specific antibody via catheter or other means of directing the
first administration of the antibody to a defined organ that
contains the cross-reactive antigen where the tumor to be treated
is disseminated outside of the organ. Unconjugated irrelevant
antibody and/or detoxified, conjugated, nonspecific antibody are
injected by peripheral vein. Conjugated specific antibody is then
injected intravenously.
3. Reducing Antiglobulin Response Directed at the Specific
Antibody
Irrelevant antibody is administered prior to or simultaneously with
specific antibody or specific antibody conjugate. The irrelevant
antibody may be administered in higher doses than the specific
antibody. In one preferred embodiment, the irrelevant antibody is
whole immunoglobulin and the specific antibody is an antibody
fragment (see Example V). In another preferred embodiment, the
ratio of specific to nonspecific antibody body ranges from about
1:1 to about 1:100 and is preferably 1:5. In another preferred
embodiment, the nonspecific antibody is whole immunoglobulin and
the specific antibody is Fab or Fv. The basis for this strategy is
that the higher dose and use of whole, not fragment, of the
irrelevant antibody is more likely to evoke an immunological
response than the lower dose and less immunogenic fragments of
specific antibody.
When a patient develops antiglobulins that bind to the irrelevant
antibody but not the specific antibody, the same irrelevant
antibody may be administered in a subsequent dose ahead of specific
antibody to adsorb the circulating antiglobulin and in higher doses
to block nonspecific sites in normal tissues. Any antiglobulins to
irrelevant antibody that cross-react with specific antibody would
be complexed and deposited in the kidney or reticuloendothelial
system, depending on the size of the complex. Most importantly,
conjugated specific antibody given subsequently would not be
complexed, but would be free to bind to target cells.
Alternatively, a second irrelevant antibody that is not recognized
by the antiglobulin response may be substituted in subsequent
injections. A combination of irrelevant antibodies may also be
used.
EXAMPLES
Reducing Nonspecific Uptake
Monoclonal antibody (Mab) NR-2AD is a murine IgG.sub.2a
immunoglobulin that was designed as an anti-idiotype that bound to
a single patient's B-cell lymphoma and to no other human tissue.
MAb 9.2.27 is a murine IgG.sub.2a antibody that recognizes the 250
Kilodalton glycoprotein/proteoglycan melanoma-associated antigen.
Both were scaled up by in vitro cell culture, purified by column
chromatography, and tested for purity and sterility to meet the
draft guidelines for injectable monoclonal antibodies from the
Office of Biologics, Food & Drug Administration ("Points to
consider in the manufacture of injectable monoclonal antibody
products intended for human use in vivo: Revised draft of Jun. 11,
1984"). MAb 9.2.27 was digested with pepsin and the F(ab)'.sub.2
fragment purified from residual intact antibody.
NR-2AD 50 mg was diluted in normal saline and injected
intravenously into patient 8501.08 who had metastatic malignant
melanoma. One hour later, 2.5 mg Tc-99 m labeled 9.2.27
F(ab)'.sub.2 was administered intravenously. The patient's blood
was withdrawn and counted with a Tc-99 m standard. Surprisingly,
the serum half-life (t1/2) of the labeled F(ab)'.sub.2 was 17
hours. The average serum t1/2 of the labeled 9.2.27 F(ab)'.sub.2
for patients receiving NR-2AD was 12 hours compared to 6 hours for
those who did not receive NR-2AD prior to the labeled fragment. The
patient's tumor was visualized by gamma camera imaging and then
excised. Another unexpected result was the detection of a tumor
that weighed only 0.25 gm.
II. Reducing Cross-Reactive Binding Specific Antibody
Conjugates
A. Cold-specific antibody blocks uptake of conjugated specific
antibody in normal organs
The effect of reducing cross-reactive uptake of a radiolabeled
monoclonal antibody preparation was assessed in the context of a
diagnostic imaging clinical trial. The patient (#8501.22) examined
in the study was a 32-year-old-male with a metastatic melanoma
lesion in the left posterior portion of the neck. The lesion
consisted of a tumorinvolved lymph node measuring 2.times.2 cm.
The patient received two schedules of radiolabeled antibody three
days apart. The first schedule of antibody consisted of two doses:
a 50 mg dose of non-radiolabeled intact irrelevant antibody
(NR-2AD) administered intravenously followed 1 hour later by a 2.5
mg dose of Tc-99 m radiolabeled Fab fragment of a MAb 9.2.27. The
localization of radiolabeled within the patient was assessed by
gamma camera imaging over a 7 hour period. The second schedule was
identical, except that 7.5 mg of non-radiolabeled F(ab)'.sub.2
fragment of 9.2.27 was administered 5 minutes prior to the
radiolabeled Fab preparation. The 50 mg dose of intact irrelevant
antibody was administered in both schedules, in order to reduce
nonspecific uptake of the radiolabeled antibody into normal
tissues. The non-radiolabeled target specific F(ab').sub.2
preparation was administered for the purpose of reducing
cross-reactive uptake of the radiolabeled antibody by non-target
tissues.
The results of the study showed that omission of the
non-radiolabeled target-specific antibody (9.2.27 F(ab').sub.2 was
accompanied at 7 hours post-infusion by uptake of radiolabeled
antibody into non-target tissue, specifically spleen, bone marrow
and kidney. The known tumor site was not imaged. Pre-infusion of
the non-radiolabeled target-specific antibody (9.2.27 F(ab').sub.2
was accompanied at the same time point by uptake in the kidney, but
no demonstrable uptake in the spleen, bone marrow or other normal
organs. This result was unexpected since the marrow and spleen
uptake had previously been assumed to be nonspecific. In addition,
the known tumor in the neck was clearly visible, confirming that
blocking cross-reactive binding sites by prior infusion of
non-radiolabeled target-specific antibody both reduced non-target
tissue localization and increased tumor localization of the
radiolabeled target-specific antibody.
B. Cold Specific Antibody Blocks Uptake of the Labeled Specific
Antibody by an Epitope-Specific Mechanism
Patient 8501.29 was a 49-year-old Caucasian male who presented with
melanoma on his back that then spread to lymph nodes under his arm.
At the time of imaging with the 99 m.sub.Tc -labeled antibodies,
the patient had presumed disease in the right axilla (recurrent),
questionable small subcutaneous metastases on his arm and back, and
diffuse hepatic involvement, as evidenced by CT scan and elevated
hepatic transaminases.
The purpose of the text in this patient was to determine if the
cold-specific antibody blocked normal tissue accumulation of the
labeled antibody in an antigen-binding site (i.e., epitope
specific) manner. Two antibodies, NR-ML-05 and 9.2.27, that each
recognized distinct epitopes of the 250 Kd.
glycoprotein/proteoglycan melanomaassociated antigen were chosen
for this study.
For the first procedure, the patient received irrelevant antibody
NR-2AD (NRX 900.00), cold-specific 9.2.27 (NRX-112), and then
radiolabeled NR-ML-05 (NRX 118.03) so that the cold-specific
blocker and the labeled antibody recognized distinct epitopes of
the same antigen. Gamma camera imaging 4 and 8 hours after
injection revealed hepatic metastases, an axillary chain of nodes,
but also images of marrow (sternum and pelvis) and spleen. A repeat
procedure was identical but substituted NR-ML-05 (NRX 118) as the
cold-specific blocker for the 9.2.27 used in the first procedure.
Gamma camera imaging revealed the same sites of disease, but this
time with the absence of marrow (sternum and pelvis) and splenic
uptake of the label.
This example, using the same patient as his own control,
demonstrated conclusively that the cold-specific antibody blocked
uptake of the labeled specific antibody into normal organs in an
epitope-specific manner.
III. Directed Infusion to Reduce Cross-Reactive Binding
Percutaneous catheterization of the celiac and/or pancreatoduodenal
arteries is performed through the femoral artery. MAb NR-CO-1 that
reaches with colon carcinoma and cross-reacts with normal pancreas
is labeled with Tc-99 m. Unlabeled NR-CO-1 F(ab)'.sub.2 fragments
(10 mg) are injected by 10 minute infusion through the catheter
followed by a normal saline flush (directed infusion). At the end
of the directed infusion, the labeled NR-CO-1 (2.5 mg) is injected
by peripheral vein. Omitting the directed infusion results in
increased localization in the pancreas of the subsequently
administered, labeled antibody, indicating that the directed
infusion can selectively reduce binding of conjugates in organs
containing cross-reactive antigen.
IV. Reducing Nonspecific Binding of Conjugates
Pseudomonas exotoxin (PE) and diphtheria toxin (DT) are bacterial
proteins that interfere with protein synthesis in cells by
ADP-ribosylation of elongation factor-2 (EF-2). DT binds to
nicotinamide at glutamic acid in position 148 in the molecule.
Substitution of aspartic acid in this position (DT.sub.ASP) reduces
the activity of DT to 1% of the native molecule, but does not
affect its binding to cells. PE is thought to have a "pocket" for
binding to its substrate that contains a tyrosine (position 481)
and glutamic acid (position 553). Iodination of tyrosine 481
(PE.sub.tyrl) is expected to result in >50% loss in activity of
PE (PE.sub.tyrl) but retention of its binding ability.
NR-2AD (irrelevant immunoglobulin) is reacted with 25 mM
dithiothreitol and PE.sub.tryl or DT.sub.ASP with SMPB
[succinimidyl(4-p-maleimidophenyl) butyrate], and the unreacted
reagents are removed. The derivatized antibody and toxin are mixed
together, producing NR-2AD-S-C-PE.sub.tryl or NR-2AD-S-C-DT.sub.ASP
(detoxified conjugates) that are purified by column chromatography,
20-500 mg of the detoxified conjugates is administered
intravenously prior to administration of NR-ML-05-S-C-PE or
NR-ML-05-S-C-DT (specific toxin conjugates). NR-ML-05 is a murine
monclonal antibody that recognizes a 250 kilodalton
glycoprotein/proteoglycan human melanoma-associated antigen.
The prior administration of the detoxified conjugates is expected
to reduce specific conjugate binding in normal nonspecific sites
(nonspecific has two components in this example, viz, the
nonspecific binding of the irrelevant immunoglobulin part of the
conjugate and the nonspecific binding of the modified toxin). The
specific toxin conjugate is then injected intravenously in doses
two times or greater than could be given without the blockade of
non-specific sites with detoxified conjugates. Additionally,
unconjugated NR-2AD and unconjugated NR-ML-05 are given prior to
the specific toxin conjugates. These methods permit the
administration of higher doses of potent immunoconjugate for
increased localization and improved tumor reduction.
V. Reducing Antiglobulin Response Directed at a Specific
Antibody
The effect of co-administration of an irrelevant monoclonal
antibody (NR-2AD) on subsequent antiglobulin development to a
specific MAb (9.2.27) was assessed in the context of a diagnostic
imaging trail. Sixteen patients with metastatic malignant melanoma
received 1 to 25 mg doses of Tc-99 in radiolabeled 9.2.27 monclonal
antibody of fragments thereof, preceded by 5 minutes by doses of
7.5 to 9 mg of non-radiolabeled 9.2.27 or fragments thereof. Thus,
patients received total doses of 10 mg of the 9.2.27 antibody and
its fragments. One hour prior to administration of the specific
antibody, 50 mg doses of a non-radiolabeled intact irrelevant
antibody (NR-2AD) was administered to 11 of 16 patients.
Serologic evidence of an antiglobulin response was evaluated using
a solid-phase, enzyme-linked immunoassay (ELISA) employing either
the target-specific (9.2.27) or irrelevant (NR-2AD) antibody as the
capture antigen. Serum specimens were evaluated from time points
ranging from 2 weeks to over 6 months following treatment. Six of
the eleven patients evaluated receiving NR-2AD demonstrated
evidence of an antiglobulin response to the irrelevant NR-2AD
antibody of greater magnitude than that which was obtained in the
upper 95th percentile of 60 healthy controls. In the same group of
eleven patients, only one person demonstrated an antiglobulin
response to the target-specific 9.2.27 antibody above the 95th
percentile of the healthy control population.
These data indicate that prior administration of a 5-fold excess of
an irrelevant MAb preparation resulted in antiglobulin responses,
in those individuals who developed an antiglobulin response, which
was skewed toward the irrelevant rather than the target-specific
MAb.
VI. Repeated Administration of Antibody in the Presence of
Antiglobulins
Patient #8501.08 in the 99 m.sub.Tc imaging trail of melanoma
received two imaging procedures within a one-week period with the
9.2.27 melanoma-specific antibody and the NR-2AD irrelevant
antibody. The patient returned after 8 months and was repeat imaged
with the NR-ML-05 melanoma specific antibody and the NR-2AD
antibody. At that time, the patient had developed a 19-fold
increase in antiglobulin directed to the NR-2AD antibody. After
premedication with 50 mg diphenhydramine, the patient received
NR-2AD41 mg diluted in normal saline slowly over 60 minutes. He
then received 10 mg NR-ML-05 cold-specific antibody followed by
NR-ML-05 Fab labeled with 99 m.sub.Tc. The labeled antibody showed
no evidence of altered biodistribution and successfully targeted
known subcutaneous and liver tumors.
By contrast, studies in normal guinea pigs immunized with murine
monoclonal antibodies and imaged with either the same or an
irrelevant .sup.99 m Tc-labeled antibody demonstrated that the
presence of specific antiglobulin altered biodistribution of
labeled antibody. Administration of a radiolabeled antibody to
which antiglobulin was reactive resulted in biodistribution of the
radiolabeled to liver and spleen. If the circulating antiglobulin
was not specific for the radiolabeled antibody, then
biodistribution was indistinguishable from biodistribution in the
non-immunized animal.
From the foregoing, it will be appreciated that, although specific
embodiments of the invention have been described herein for
purposes of illustration, various modifications may be made without
deviating from the spirit and scope of the invention. Accordingly,
the invention is not limited except as by the appended claims.
* * * * *